We bring to your notice a new website where you can buy propecia australia at a low cost with fast delivery to Australia.


1Cubist Pharmaceuticals, Inc., Lexington, MA ; 2Axistat, Inc., San Francisco, CA
Background: CXA-101 is a novel parenteral broad-spectrum cephalosporin with excellent in vitro activity against
Primary Outcome: microbiological response at the TOC visit, Table 2 Pseudomonas aeruginosa and most Enterobacteriaceae.
n In total, 129 subjects were enrolled; 86 in the CXA-101 group and 43 in the ceftazidime group, Figure 2 n In the mMITT population, microbiologic cure rates were 83.1% for CXA-101 and 76.3% for ceftazidime Table 5. TEAEs Occurring in ≥3% of Subjects in Either Treatment Arm Methods: This Phase 2 study compared the microbiological outcome and safety of CXA-101 vs. ceftazidime (2:1),
q 2 subjects (1 in each arm) were randomized but not treated n In the ME population microbiologic cure rates were 85.5% for CXA-101 and 92.6% for ceftazidime both 1g q8h IV for 7 to 10 days, in adult subjects with cUTI, including pyelonephritis. Eligibility for the micro intent- BASELINE
to-treat (mITT) population required isolation of at least one (but no more than two) pathogen(s) at ≥ 105 CFU/mL (6 to 9 Days After
(21 to 28 Days After
n 103/129 (80%) subjects with a cUTI had qualifying urine culture n Microbiological cure rates in the mMITT were slightly lower for cLUTI versus pyelonephritis, but were (Day -2 to 1)
(Days 1 to 10)
from a baseline urine culture. To be micro evaluable (ME), a urine culture obtained at the test-of-cure visit (6 - 9 days 82 subjects were microbiologically evaluable post therapy) and adherence to the protocol were required.
Demographics and baseline characteristics for the MITT and ME populations are summarized in Table 1 Results: 129 subjects were enrolled (86 CXA-101, 43 ceftazidime); 103 had a qualifying urine culture (mITT), 82 were
Both treatments effectively achieved high clinical response rates at the TOC, Table 3 ME. The baseline characteristics were similar in the two treatment groups, 33% had pyelonephritis. Micro cure rates q E.coli was the most frequently isolated pathogen (70/103 in the MITT Population) in the mITT population at TOC were 83% and 76% in the CXA-101 and ceftazidime groups, respectively, and in the n Eradication rates at the TOC in subjects with E. coli, the most common pathogen, were 91.7% in the ME population were 86% and 93%, respectively. Eradication rates in subjects with E. coli, the most common CXA-101 group and 94.7% in the ceftazidime group, Table 4 pathogen, were 92% and 95% in the CXA-101 and ceftazidime groups, respectively. Clinical response rates in the n Sustained clinical cure rates at the late follow-up visit (3 to 4 weeks post therapy) were 98.0% for mITT were 91% and 92% with CXA-101 and ceftazidime, respectively. Sustained clinical cure rates at the late follow- Figure 2. Schematic of Analysis Populations and Distribution of Patients up visit (3 to 4 weeks post therapy) were 98% for CXA-101 and 93% for ceftazidime. Both treatments were well tolerated; there were no deaths and only 1 serious adverse event; recurrent pyelonephritis in the CXA-101 group. The most common adverse events were constipation (9% vs 5%), sleep disorder (7% vs 5%), and diarrhea (4 vs 7%). The Table 2. Microbiological Response (Cure) at the TOC Visit, n/N (%) incidence and pattern of adverse events were similar in the 2 treatment groups; only 3% of adverse events were severe.
Conclusions: CXA-101 showed high micro and clinical efficacy in adult subjects with cUTI, similar to ceftazidime.
n Hospitalized male or non pregnant female subjects, 18 to 90 years inclusive Both drugs were well tolerated. The results support the further development of CXA-101 for serious gram negative n Demonstrated clinical signs and/or symptoms of cUTI (including pyelonephritis) Creatinine clearance (CrCl) ≥ 50 mL/min n Availability of a study qualifying pre-treatment urine specimen within 48 hours prior to receipt of 1st dose n Receipt of any amount of potentially therapeutic antibacterial therapy after collection of the pretreatment baseline urine culture and before the 1st first dose of study drug Table 3. Clinical Response (Cure) at the TOC Visit, n/N (%) Urinary tract infections (UTIs) are prevalent in society and their financial burden is significant. In the United n Receipt of >1 dose of a potentially therapeutic antibacterial agent for the treatment of the current cUTI States, UTIs account for more than 100,000 hospital admissions annually and up to 40% of all hospital- within 96 hours before obtaining the study-qualifying pretreatment baseline urine acquired infections [1]. Complicated UTIs (cUTIs) and pyelonephritis are defined as clinical syndromes in n Moderate or severe impairment of renal function (CrCl < 50 mL/min, requirement for peritoneal dialysis, n This is the first clinical study of CXA-101 conducted in a patient population men or women characterized by the development of the systemic and local signs and symptoms of fever, hemodialysis or hemofiltration, or oliguria) n Overall, the demographics and baseline characteristics of the study population were generally similar chills, malaise, flank pain, back pain, and costo-vertebral angle pain or tenderness, occurring in the presence of an abnormality of the urinary tract or in the presence of catheterization [2]. Gram-negative organisms account for approximately 60 to 80% of complicated and nosocomially acquired UTIs [3]. Microbiological outcome at the Test-of-Cure Visit n The results showed that CXA-101 was therapeutically effective and its activity comparable to ceftazidime across different analysis sets, regions, and in both cUTI diagnosis groups (cLUTI and pyelonephritis) CXA-101 is a novel parenteral cephalosporin, being developed for the treatment of serious bacterial infections.
CXA-101 displays potent antibacterial activity in-vitro against common gram-negative and selected gram- • A urine culture at TOC shows all uropathogens found at baseline at ≥ 105 CFU/mL are reduced to n Although not considered clinically significant, the disparity in cure rates between treatment groups in the positive organisms. Its anti-pseudomonal activity is the most potent among all currently available beta- ME population are likely due to the uneven distribution of some variables despite randomization e.g. lactams, including the cephalosporins and carbapenems. CXA-101 has broad-spectrum antibacterial Table 4. Per-Pathogen Microbiologic Eradication Rate (ME Population) coverage against beta-lactam-resistant Enterobacteriaceae and multi-drug resistant P. aeruginosa. q 6 subjects in CXA-101 group compared with none in the ceftazidime group had P. aeruginosa – • A urine culture, taken any time after the completion of therapy, with ≥ 104 CFU/mL of the (a pathogen known to confer a higher risk for adverse clinical and microbiologic outcomes in cUTI) n No clinically important unexpected safety signals were observed in this study.
• No interpretable urine culture at the TOC visit and the pathogen was not already classified as Table 1. Demographics and Baseline Characteristics Primary objective was to determine the microbiological response 6-9 days after treatment with CXA-101, n Clinical outcome at the End of Therapy and Test-of-Cure Visits Resolution of, marked improvement in, or return to pre-infection signs and symptoms and no use n Secondary objectives included: evaluating the safety of CXA-101 in subjects with cUTI, evaluating the clinical of additional antimicrobial therapy for the treatment of the cUTI response at the TOC visit, and determining the pharmacokinetic profile of CXA 101 in subjects with cUTI.
• Persistence of one or more sign or symptom of infection or reappearance of signs and symptoms n CXA-101 showed high microbiologic and clinical efficacy versus ceftazidime that requires additional or alternative antimicrobial therapy for the current cUTI (or) n CXA-101 appeared safe and well tolerated in this group of adult subjects with cUTI • Adverse event leading to study drug discontinuation and the subject requires alternative antimicrobial therapy for the current cUTI n These results support the further development of CXA for serious gram negative infections MSSA = Methicillin-susceptible Staphylococcus aureus • Study data are not available for the evaluation of clinical outcome for any reason or the outcome n This was a Phase 2, multicenter, prospective, randomized, double-blind, efficacy and safety study comparing intravenous CXA-101 (1000 mg q8h) and intravenous ceftazidime (1000 mg q8h) n Treatment-emergent adverse events (TEAEs) occurred in 47.1% (40/85) of subjects receiving CXA-101 and 38.1% (16/42) of subjects receiving ceftazidime n The study sample size was 120 subjects, randomized 2:1 to CXA-101 or ceftazidime n Inferential statistical analyses were not conducted n Subjects were stratified by baseline diagnosis: either complicated lower UTI (cLUTI) or pyelonephritis q Of these, only 1 was considered serious; recurrent pyelonephritis in a CXA-treated subject q Intent-to-Treat (ITT) Population: all randomized subjects n The incidence and pattern of AEs were generally similar in the 2 treatment groups, Table 5 Modified-ITT (MITT) Population: all randomized subjects who receive any amount of study drug (safety n Four subjects (2 in each treatment group) had TEAEs assessed as severe including abdominal pain and n The study design is outlined in Figure 1 worsening anemia in the CXA-101 group and chest pain and aggression in the ceftazidime group Wagenlehner FME, Naber KG. Treatment of bacterial urinary tract infections: presence and future. Eur n A study-qualifying pretreatment baseline urine culture was required within 48 hours before the start of q Microbiological-MITT (mMITT) Population: subjects in the MITT Population who had at least one All severe events were assessed as unrelated to study treatment administration of the 1st dose of study drug, acceptable causative pathogen from a study-qualifying pretreatment baseline urine specimen n Two subjects discontinued study drug due to AEs, one subject in the CXA-101 group whose CrCl Food and Drug Administration. Complicated Urinary Tract Infections and Pyelonephritis - Developing n No oral antibiotic therapy was permitted q Microbiologically Evaluable (ME) Population: subjects in the mMITT Population who met the minimal decreased to <50 mL/min on Day 3, and one in the ceftazidime group who discontinued because of Antimicrobial Drugs for Treatment, Draft Guidance for Industry. July 1998.
disease criteria, had no protocol deviation likely to impact the microbiological outcome, received an n Microbiological and clinical response was assessed at the EOT, TOC & LFU visits Wagenlehner FME, Pilatz A, Naber KG, Perletti G, Wagenlehner CM, Weidner W. Anti-infective treatment appropriate duration of study drug therapy, had an interpretable urine culture at the TOC visit, and n Safety was monitored through the review of vital signs, laboratory and physical examinations and the of bacterial urinary tract infections. Curr Med Chem 2008;15:1412-27.
attended the TOC visit (or was classified as a microbiological failure before the TOC visit) This study was funded by Cubist Pharmaceuticals.
50th Interscience Conference on Antimicrobial Agents and Chemotherapy September 12 −15, 2010, Boston, MA, USA

Source: http://www.cubist-pharmaceuticals.net/downloads/Umeh_ICAAC2010_08144v2.pdf


SAVON SANOMAT 11 Toimitus: Matti Pietiläinen (esimies), Kari-Pekka Issakainen, Jouko Juutilainen, Sähköposti: [email protected], [email protected] Arava-asuntojen vuokri n tulee isoja korotuksia M-lähikauppa Säyneisi n sosiaaliviraston asunnottomien ketut vastikkeet ovat nousseet nousun jatkumiseen. Talous- PeeÄssän Salen tilalle ria on korotettu vai

Microsoft word - cme schedule at a glance 3 25 12

DRAFT SCHEDULE** (Times and Speakers Subject to Change) Marriott World Center SCHEDULE-AT-A-GLANCE THURSDAY, May 17, 2012 PRE-CONFERENCE WORKSHOPS: REGISTRATION OPENS 9:00 am – 6:00 pm Putting it all Together: The Nuts and Bolts of Sangeeta Pati, MD Hormone Restoration in Men and Women 9:00 am – 5:00 pm Transforming Theoretical Into Practical: A Lena Ed

Copyright © 2010-2014 Medical Science